Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2021.07.27

Sai Life Sciences Wins Golden Peacock National Training Award 2021

Sai Life Sciences Wins Golden Peacock National Training Award 2021

Sai Life Sciences, one of India’s fastest growing Contract Research, Development & Manufacturing Organizations (CRDMOs), today announced that it has been honoured with the Golden Peacock National Training Award 2021 in the pharmaceutical category. This is the second consecutive Golden Peacock Award for the company following the Golden Peacock National Quality Award it received in 2020.

Making the announcement, Chief Quality Officer of Sai Life Sciences, Dr M Damodharan said, “Being in a knowledge-intensive industry, we foster the skills and competencies of our people through best-in-class L&D practices spanning holistic training, systematized governance, and user convenience. But it is the willingness with which our associates adopted the online training system that has allowed us to sustain superior compliance standards of over 99.5% in the last two years. I dedicate this this prestigious recognition to all Saimers.”

Golden Peacock Awards are the most coveted awards for corporate excellence in India organized every year under the aegis of the Institute of Directors, India. A grand jury under the chairmanship of Hon’ble Justice M. N. Venkatachaliah, former Chief Justice of India and former Chairman, National Human Rights Commission of India and National Commission for Constitution of India Reforms, had received 311 applications this year out of which 147 applications were shortlisted for various categories of awards including Business Excellence, Innovative Product/Service and Quality.

Earlier this year, Sai Life Sciences won two awards at the prestigious, US-based Association for Talent Development – Excellence in Practice (ATD-EIP) awards 2021 in categories of ‘Learning Technologies’ and ‘Change Management’. The company has mapped the learning needs of over 100 unique roles across the organization and provides holistic training across quality, technical, safety, soft skills and more, with interactive audio-visual resources delivered through a robust learning management system.

Over the past three years, the company has invested US$100M to expand and upgrade its R&D and manufacturing facilities, induct top-notch global scientific and leadership talent, strengthen automation and data systems, and above all raise the bar for safety, quality and customer focus. With over two decades of experience in advancing its clients’ drug discovery programmes and recent transformational investments, the company is today poised to play a more significant role in accelerating the discovery, development, and manufacturing of complex small molecules for innovator pharma and biotech companies.
The company’s commitment to best practices of sustainability and principled governance have been recognized with an award at the prestigious 21st National Award for Excellence in Energy Management 2020 by CII - Sohrabji Godrej Green Business Centre, and a 5-Star rating for Excellence in EHS Practices at the Confederation of Indian Industry (CII) South awards 2019.

Share article

More News

2025.09.05

Reviving Kudikunta Lake: Bringing nature and community closer together

As part of its Corporate Social Responsibility initiative, Sai Life Sciences has taken up the development of Kudikunta Lake in Hyderabad, reinforcing its commitment to sustainability and community well-being. The Kudikunta Lake initiative marks a significant step in restoring one of Hyderabad’s key lakes and advancing the cause of sustainable urban living. The company has […]
Read more

2025.09.05

From injections to pills: oral peptides set to transform drug development

In a recent article published in Drug Target Review, Dr Santosh Kulkarni highlights the shift from injections to pills. He writes about how oral peptide therapeutics are overcoming the long-standing challenge of poor bioavailability—bringing us closer to patient-friendly medicines without compromising efficacy. The article highlights the booming peptide drug market and the scientific advances—from chemical […]
Read more

2025.08.28

Sai Life Sciences completes Phase II of Production Block 11 at Bidar site, India, expands capacity to 700 KL

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the completion of Phase II of its new Production Block (PB-11) at the company’s flagship API manufacturing facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL, was inaugurated […]
Read more

2025.08.20

Sai Life Sciences secures SBTi validation for near-term climate targets

Sai Life Sciences Limited, an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its near-term targets to cut greenhouse gas (GHG) emissions have been validated by the Science Based Targets initiative (SBTi)—a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. […]
Read more

2025.08.20

Sai Life Sciences featured in Drug Discovery & Development on trends shaping drug discovery

Sai Life Sciences was recently featured in Drug Discovery & Development, where Dr Maneesh Pingle, Executive Vice President and Head of Discovery Services, shared insights on the emerging trends in pharma sector. A key focus was the impact of GLP 1 agonists in accelerating peptide drug discovery. Dr. Pingle explained how the success of these […]
Read more